Status:
RECRUITING
The NOrdic-Baltic Randomized Registry Study for Evaluation of PCI in Chronic Total Coronary Occlusion
Lead Sponsor:
Leif Thuesen
Conditions:
Chronic Total Occlusion of Coronary Artery
Heart Failure
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Randomized registry for the study of CTO PCI as adjunction to optimal medical therapy.
Eligibility Criteria
Inclusion
- ≥1 CTO lesion amenable to PCI.
- Stable and stabilized coronary artery disease
- Symptoms (angina pectoris or shortness of breath) and/or signs of reversible perfusion defect by SPECT, PET or MR and/or angiographic/echocardiographic indication of reversible ischemia.
- CTO lesion in a major coronary vessel supplying a significant myocardial territory (vessel diameter usually ≥3mm).
Exclusion
- Expected survival \<1 year.
- Renal failure on dialysis.
- Stable non-CTO lesions treated within one month.
- Declined informed consent.
- Regarding CMR: allergy to contrast medium, severe obesity, claustrophobia and certain metallic implants
Key Trial Info
Start Date :
June 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2030
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT03392415
Start Date
June 1 2018
End Date
July 1 2030
Last Update
August 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aalborg University Hospital
Aalborg, Denmark, 9100